- Home
- GLUE vs THRM Comparison
GLUE vs THRM Comparison
Compare GLUE & THRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLUE | THRM |
|---|---|---|
| Founded | 2019 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.4B |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GLUE | THRM |
|---|---|---|
| Price | $11.80 | $35.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $32.00 | ★ $37.20 |
| AVG Volume (30 Days) | ★ 1.0M | 268.9K |
| Earning Date | 05-08-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.28 |
| Revenue | $123,672,000.00 | ★ $554,979,000.00 |
| Revenue This Year | N/A | $4.96 |
| Revenue Next Year | $2.45 | $7.12 |
| P/E Ratio | ★ $72.42 | $121.04 |
| Revenue Growth | ★ 63.54 | 50.16 |
| 52 Week Low | $7.09 | $27.00 |
| 52 Week High | $25.77 | $48.35 |
Technical Indicators
Market Signals| Indicator | GLUE | THRM |
|---|---|---|
| Relative Strength Index (RSI) | 29.33 | 36.11 |
| Support Level | N/A | $34.15 |
| Resistance Level | $15.00 | $39.14 |
| Average True Range (ATR) | 0.65 | 1.37 |
| MACD | -0.01 | -0.39 |
| Stochastic Oscillator | 10.56 | 26.97 |
Price Performance
Historical ComparisonAbout GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
About THRM Gentherm Inc
Gentherm Inc is an automotive parts manufacturer. The business activities of the group function through the Automotive and Medical segments. The vast majority of the firm's revenue comes from the Automotive segment, which includes automotive climate comfort systems, automotive cable systems, battery performance solutions, and automotive electronics and software systems. The medical segment is comprised of the results from the patient temperature management business in the medical industry. Its geographical segments are the USA, China, South Korea, Germany, Japan, the Czech Republic, and other countries.